The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
The ruling comes against the backdrop of a mounting trauma burden in India, where nearly 4.67 lakh accidental deaths occur annually
From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies
BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes
The company highlighted continued demand strength and pricing resilience despite global disruptions
POSEIDON is among the largest global datasets to quantify this residual inflammatory burden
These data support clinically meaningful efficacy within this patient population. We observed a high rate of complete responses in patients with laCSCC
India already has talent, digital infrastructure, entrepreneurial energy, clinical expertise, and policy momentum. The next phase demands coordinated execution and building institutions that can hold the ecosystem together over time
Subscribe To Our Newsletter & Stay Updated
